SCHEMBL9157123

SCHEMBL9157123

CCCn1c(=O)n(Cc2ccccc2)c(=O)c2nc(-c3ccc(C=CC(=O)O)cc3)[nH]c21

nearest known ligand 0.65

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ADORA2B P29275 17/20 0.65
▸ ADORA2A P29274 11/20 0.62
▸ ADORA3 P0DMS8 9/20 0.62
▸ ADORA1 P30542 6/20 0.62
▸ KDM4E B2RXH2 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9157110 1.00 ADORA2B (0.65) ADORA2BADORA2AADORA3ADORA1KDM4E
SCHEMBL9155034 0.96 ADORA2B (0.65) ADORA2BADORA2AADORA3ADORA1KDM4E
SCHEMBL9155023 0.96 ADORA2B (0.65) ADORA2BADORA2AADORA3ADORA1KDM4E
SCHEMBL9637190 0.95 ADORA2B (0.63) ADORA2BADORA2AADORA3ADORA1KDM4E
SCHEMBL9637193 0.95 ADORA2B (0.63) ADORA2BADORA2AADORA3ADORA1KDM4E
SCHEMBL6554070 0.93 ADORA2B (0.72) ADORA2BADORA2AADORA3ADORA1KDM4E
SCHEMBL6554077 0.93 ADORA2B (0.72) ADORA2BADORA2AADORA3ADORA1KDM4E
SCHEMBL6555021 0.92 ADORA2B (0.73) ADORA2BADORA2AADORA3ADORA1KDM4E
SCHEMBL6555024 0.92 ADORA2B (0.73) ADORA2BADORA2AADORA3ADORA1KDM4E
SCHEMBL9637073 0.91 ADORA2B (0.61) ADORA2BADORA2AADORA3ADORA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0639055-A1 METHODS OF TREATING OBESITY WITH PURINE RELATED COMPOUNDS THE PENN STATE RESEARCH FOUNDATION (US) 1995-02-22 — — EP claimed
WO-1993021783-A1 METHODS OF TREATING OBESITY WITH PURINE RELATED COMPOUNDS THE PENN STATE RESEARCH FOUNDATION (US) 1993-11-11 — — WO claimed
US-5017577-A Using Purine Cinnamic Acids BURROUGHS WELLCOME CO. (US) 1991-05-21 — — US claimed
US-4879296-A BLOCKING ADERNOSINE CELL SURFACE EFFECTS BURROUGHS WELLCOME CO. (US) 1989-11-07 — — US claimed
EP-0203721-A2 8-Phenyl xanthines THE WELLCOME FOUNDATION LIMITED (GB) 1986-12-03 — — EP claimed
EP-0639055-A1 METHODS OF TREATING OBESITY WITH PURINE RELATED COMPOUNDS THE PENN STATE RESEARCH FOUNDATION (US) 1995-02-22 — — EP disclosed
US-5300298-A Methods of treating obesity with purine related compounds THE PENNSYLVANIA RESEARCH CORPORATION (US) 1994-04-05 — — US disclosed
WO-1993021783-A1 METHODS OF TREATING OBESITY WITH PURINE RELATED COMPOUNDS THE PENN STATE RESEARCH FOUNDATION (US) 1993-11-11 — — WO disclosed
EP-0243192-B1 ANTIVIRAL 8-PHENYLXANTHINES THE WELLCOME FOUNDATION LIMITED (GB) 1992-07-15 — — EP disclosed
EP-0203721-B1 8-PHENYL XANTHINES THE WELLCOME FOUNDATION LIMITED (GB) 1992-06-10 — — EP disclosed
US-5017577-A Using Purine Cinnamic Acids BURROUGHS WELLCOME CO. (US) 1991-05-21 — — US disclosed
US-5015647-A Using Purine Cinnamic Acid Compounds BURROUGHS WELLCOME CO. (US) 1991-05-14 — — US disclosed
US-4981857-A ADENOSINE ANTAGONIST BURROUGHS WELLCOME CO. (US) 1991-01-01 — — US disclosed
US-4879296-A BLOCKING ADERNOSINE CELL SURFACE EFFECTS BURROUGHS WELLCOME CO. (US) 1989-11-07 — — US disclosed
EP-0243192-A2 Antiviral 8-Phenylxanthines THE WELLCOME FOUNDATION LIMITED (GB) 1987-10-28 — — EP disclosed
EP-0203721-A2 8-Phenyl xanthines THE WELLCOME FOUNDATION LIMITED (GB) 1986-12-03 — — EP disclosed
Send feedback